169 related articles for article (PubMed ID: 25955318)
1. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B; Li S; Jin X; Liu L
BMC Cancer; 2021 Apr; 21(1):452. PubMed ID: 33892654
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
Zhang M; Luo SC
Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
[TBL] [Abstract][Full Text] [Related]
4. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
5. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
6. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling via bioinformatics analysis reveals biomarkers in laryngeal squamous cell carcinoma.
Guan GF; Zheng Y; Wen LJ; Zhang DJ; Yu DJ; Lu YQ; Zhao Y; Zhang H
Mol Med Rep; 2015 Aug; 12(2):2457-64. PubMed ID: 25936657
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
10. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer.
Peng C; Ma W; Xia W; Zheng W
Mol Med Rep; 2017 Mar; 15(3):1087-1094. PubMed ID: 28075450
[TBL] [Abstract][Full Text] [Related]
12. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
Zheng L; Li L; Lu Y; Jiang F; Yang XA
Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis of gene expression profile data to screen key genes involved in intracranial aneurysms.
Guo T; Hou D; Yu D
Mol Med Rep; 2019 Nov; 20(5):4415-4424. PubMed ID: 31545495
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
16. Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data.
Quan L; Wang Y; Liang J; Shi J; Zhang Y; Tao K
Tumori; 2015; 101(4):368-74. PubMed ID: 25983087
[TBL] [Abstract][Full Text] [Related]
17. Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis.
Wen X; Liu S; Cui M
Biomed Res Int; 2020; 2020():3598417. PubMed ID: 32685473
[TBL] [Abstract][Full Text] [Related]
18. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells.
Szenajch J; Szabelska-Beręsewicz A; Świercz A; Zyprych-Walczak J; Siatkowski I; Góralski M; Synowiec A; Handschuh L
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287223
[TBL] [Abstract][Full Text] [Related]
20. Screening the molecular targets of ovarian cancer based on bioinformatics analysis.
Du L; Qian X; Dai C; Wang L; Huang D; Wang S; Shen X
Tumori; 2015; 101(4):384-9. PubMed ID: 25953442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
